Portfolio
The microbiome:
Essential for health.
Harnessed for medicine.
The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting microbiome disruption can increase susceptibility to immune disorders, infections, neurological conditions, cancer, and other serious conditions. New therapeutics that deliver beneficial microbial communities hold the promise of transforming patient outcomes in a wide range of therapeutic areas with serious unmet patient needs.
Our portfolio
Finch has established a leading portfolio of microbiome assets designed with insights from human microbiota transplantation studies. These studies involve the transfer of microbiota from healthy individuals to individuals with disease, an area of intense research with hundreds of third-party clinical studies spanning dozens of different conditions.
In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.
Portfolio highlights:
CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent CDI
Pre-clinical microbiome assets designed to target ulcerative colitis (FIN-524), Crohn’s disease (FIN-525), and autism spectrum disorder (FIN-211)
Robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents
An industry leading IP estate
In collaboration with microbiome pioneers such as Dr. Thomas Borody, founder of the Centre for Digestive Diseases in Australia, Finch has established a leading patent portfolio with significant longevity and critical relevance for the microbiome field.
Extensive, multi-layered
patent protection
- >70 issued U.S. and foreign patents and >140 patent applications pending
- Robust protection for CP101 into 2036
Foundational patents
in the field
- Priority dates of foundational patent family predate the industry, enabling broad protection for composition of matter, methods of use, manufacture, and formulation claims into 2031
Broad & diverse
patent protection
- Protection for multiple microbiome product strategies, including donor-derived and donor-independent product strategies
- Diverse therapeutic coverage, with protection for a wide range of indications of interest
Finch CP101 publications
Other supporting third-party literature
Fecal Microbiota Transplantation Relieves Gastrointestinal and Autism Symptoms by Improving the Gut Microbiota in an Open-Label Study Frontiers in Cellular and Infection Microbiology
Long-Term Benefit of Microbiota Transfer Therapy on Autism Symptoms and Gut Microbiota Scientific Reports
Combined Oral Fecal Capsules Plus Fecal Enema as Treatment of Late-Onset Autism Spectrum Disorder in Children: Report of a Small Case Series Open Forum Infectious Diseases
Fecal Microbiota Transplantation for Children with Autism Spectrum DisorderGastrointestinal Endoscopy
Dissecting the Contribution of Host Genetics and the Microbiome in Complex Behaviors Cell
IL-17a Promotes Sociability in Mouse Models of Neurodevelopmental Disorders Nature
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis Inflammatory Bowel Diseases
Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial Gastroenterology
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis Inflammatory Bowel Diseases
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Journal of Crohn’s and Colitis
Fecal Microbiota Transplant Overcomes Resistance to Anti–PD-1 Therapy in Melanoma Patients Science
Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients Science
Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors Science
Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study Digestive Diseases and Sciences
Age-Related Immune Clearance of Hepatitis B Virus Infection Requires the Establishment of Gut Microbiota Proceedings of the National Academy of Sciences of the United States of America